5339W-12: Chugai NSCLC

CRC 12104: A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer

Type of Study
Cancer (Oncology) - Lung
Location
Swedish Cancer Institute
Short Description

Purpose: CH5424802 is a newly invented, selective oral ALK inhibitor.  In the Phase II portion, the efficacy of CH5424802 will be assessed at the recommended dose.

Status
Open to Enrollment
Principal Investigator
Howard (Jack) West, M.D.
Eligibility Notes
  • ECOG performance status =< 2
  • Confirmed of ALK-positive NSCLC
  • No Untreated brain metastases
  • No history of serious cardiac dysfunction
  • No clinically significant gastrointestinal abnormality that would affect the absorption of drug
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org